Drug said to be effective against early migraine symptoms
What's more, those non-headache symptoms tend to crop up before a full-fledged migraine headache takes root.
But now, researchers say they've discovered an already approved migraine drug that can stop these other symptoms hours before a headache starts.
Ubrogepant successfully warded off early migraine symptoms in patients who took the drug one to six hours before a headache, causing a 72% increased likelihood a person wouldn't experience light sensitivity and an 85% increased likelihood they wouldn't have fatigue.
Doubled likelihood they wouldn't experience neck pain or sound sensitivity.
The drug also helped people think and concentrate better despite their oncoming migraine, researchers reported Monday in Nature Medicine.
The results suggest that ubrogepant could "free patients from a disabling part of migraine," study co-author Dr. Peter Goadsby, a neuroscientist at King's College London, told Nature.
Ubrogepant gained approval from the U.S. Food and Drug Administration in 2019 after studies showed that it reduced headache pain and other migraine symptoms within two hours of taking the pill, according to Drugs.com.
The drug works by blocking a protein involved in pain and migraines called calcitonin gene-related peptide, or CGRP. Ubrogepant prevents the CGRP protein from attaching to nerve endings.
Symptoms that occur prior to a migraine are called "prodome" symptoms. Migraines occur when a brain region called the hypothalamus goes out of whack, and these prodomal symptoms precede the headache.
"Not enough attention has been given to prodrome symptoms," Goadsby said, noting that the new study was mean to "fill this gap."
For the study, researchers recruited 438 people who could reliably predict oncoming migraine attacks based on their prodomal symptoms.
People were randomly assigned to take either ubrogepant or a placebo just before a migraine attack and keep notes on their symptoms.
They then waited for their next migraine and took the opposite treatment, be it the medicine or placebo. Participants didn't know what they were taking either time.
Patients taking Ubrogepant reported:
• Better ability to concentrate within an hour
• Reduced light sensitivity within two hours
• Reduced fatigue and neck pain after three hours
• Reduced sound sensitivity after four hours
However, it is essential that people take the drug before their headache if they want to stop these other symptoms, Goadsby said.
"People who know their migraine would benefit more from this medicine," he said, arguing that doctors should train patients to detect early migraine symptoms so they can judge when to take ubrogepant.
More information
Cleveland Clinic has more on migraines.
Copyright © 2025 HealthDay. All rights reserved.
Copyright 2025 UPI News Corporation. All Rights Reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
4 hours ago
- UPI
State Department halts Gazan visitors' visas amid review
The State Department on Saturday announced a halt in visa approvals for Gazans after podcaster Laura Loomer on Friday questioned their arrivals in locations across the United States. File Photo by Louis Lanzano/UPI | License Photo Aug. 16 (UPI) -- A review of medical-humanitarian visa processing temporarily has stopped the State Department from approving visitors' visas for Gazans as of Saturday. The State Department announced the halt in visa processing for Gazans after podcaster Laura Loomer on Friday questioned flights that carry injured Gazans needing medical care into the United States, Politico reported on Saturday. Loomer reported "flights of Gazans arriving at airports all across" the United States, and the State Department reported the halt in visa processing for Gazans on Saturday. "All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days," State Department staff posted on X on Saturday morning. Neither the State Department nor Secretary of State Marco Rubio provided additional information regarding the decision. The State Department's decision comes after the Trump administration in June increased its vetting of visa applicants to include social media posts and other online activities by respective applicants. Officials in France likewise suspended the evacuation of Gazans to France after a female student identified as a "Palestinian" allegedly circulated a social media post depicting former German dictator Adolf Hitler calling for the killing of Jews, according to Fox News. French Foreign Minister Jean-Noel Barrot told media the woman must leave France and said no further evacuations of Gazans will occur while the matter is investigated to learn how she obtained a student visa. In the United States, Kent, Ohio-based non-profit HEAL Palestine is sponsoring the evacuation of injured Gazans to obtain medical care in the United States. HEAL Palestine says it has evacuated 148 Gazans, including 63 children, and brought them to the United States for medical care. The evacuees are being treated in locations across the nation, including Atlanta, Boston, San Antonio and Seattle and will return to Egypt upon completion of their medical care, the non-profit says. HEAL Palestine was founded in 2024 and says it primarily helps children between ages 6 and 15, but its numbers show it has brought more adults to the United States than children.
UPI
a day ago
- UPI
NASA seeks student entries for Human Exploration Rover Challenge
Aug. 15 (UPI) -- NASA is accepting contest entries from student teams to design, build and test rovers on the moon and Mars. In the Human Exploration Rover Challenge, students need to make models that are capable of going over a course while completing tasks for future Artemis missions, NASA said in a news release. In the challenge, teams design projects that sample of soil, water and air over a half-mile course with a simulated field of asteroid debris, boulders, erosion ruts, crevasses and an ancient streambed. There are remote-controlled and human-powered divisions. In the human one, teams will play the role of two astronauts in a lunar vehicle. They must use a custom-built tool to manually collect samples. In remote-controlled, they will provide pressurized rovers, which will contain the necessary tools to collect and test samples onboard. "NASA's Human Exploration Rover Challenge creates opportunities for students to develop the skills they need to be successful STEM professionals," Vemitra Alexander, the activity lead for the challenge at NASA's Marshall Space Flight Center in Huntsville, Ala., said. "This challenge will help students see themselves in the mission and give them the hands-on experience needed to advance technology and become the workforce of tomorrow." Entries will be accepted until Sept. 15 and the 32nd annual winners will be announced at an in-person event April 9-11, 2026, at the U.S. Space & Rocket Center near NASA Marshall. Since the program began in 1994, more than 15,000 have participated in the Rover Challenge. Many students now work at NASA or in the aerospace industry. In the 2025 contest, more than 500 students participated, representing 35 colleges and universities, 38 high schools, and two middle schools in 20 states, Puerto Rico and 16 nations. "Last year, we saw a lot of success with the debut of our remote-controlled division and the addition of middle school teams," Alexander said. "We're looking forward to building on both our remote-controlled and human-powered divisions with new challenges for the students, including rover automation." The Artemis II is scheduled to reach the moon no earlier than April 26, and a crewed Artemis III is planned for mid-2027 aboard the Orion spacecraft. The last time humans landed on the moon was 1972 on Apollo 17.
UPI
a day ago
- UPI
Argentina raises death toll from tainted fentanyl to more than 100
The government of Argentine President Javier Milei blamed blamed a local laboratory, HLB Pharma Group S.A., for the deaths of more than 100 people from contaminated fentanyl. Photo by Juan Ignacio Roncoroni/EPA Aug. 15 (UPI) -- More than 100 people are believed to have died from a batch of medical fentanyl that may have been contaminated, Argentina's government said in a statement from the presidential press office. The government blamed a local laboratory, HLB Pharma Group S.A., for the incident. The tragedy, described as one of the most serious in the country's public health history, began with the distribution of vials contaminated with multidrug-resistant bacteria -- including Klebsiella pneumoniae and Ralstonia pickettii -- used in public and private hospitals across several regions since early 2025. Although the first cases were detected in May, the death toll has continued to rise in recent days, reaching 96 confirmed deaths with at least nine more under investigation. From the presidential palace, President Javier Milei's government said the company responsible, led by businessman Ariel García Furfaro, engaged in "criminal conduct" by allowing the defective product to be distributed. The presidential press office said more than 300,000 vials of the drug were produced, about 45,000 of which were administered before recall protocols were activated. Unlike other critical medications, clinical-use fentanyl was not fully integrated into the national electronic tracking system, making it harder to detect the problem early and identify the health centers that received the contaminated vials. In a public appearance, Milei turned the health emergency into a political issue by accusing the Kirchnerist movement of having "covered up" for the laboratory's owners for years. Kirchnerism is a left-wing populist movement that blends Peronist nationalism with progressive social policies, economic interventionism and an emphasis on human rights "This is a longtime partner of the previous regime. We will not allow impunity," Milei said. He also warned that his government will seek the recusal of the federal judge handling the case if the businessman is not immediately taken into custody. The National Administration of Drugs, Food and Medical Technology said it had revoked the laboratory's authorization in February, but acknowledged there were failures in subsequent distribution controls. So far, 24 people linked to the production and distribution of fentanyl have been identified as suspects in the court case. All are barred from leaving the country and have had their assets seized, though no formal charges have been filed. At the same time, the victims' families are demanding justice. Patient organizations and health professionals have called for urgent reforms to the drug tracking system and a full audit of the health system's operations to prevent similar incidents in the future. In a press release, HLB Pharma Group said it is "at the disposal of the courts" and accused political and economic sectors of "opportunism" in carrying out a "media smear campaign" against the company. The company also said that "contamination such as that reported by some media -- involving one or more multidrug-resistant bacteria typically found in a hospital setting in the same batch -- is simply not possible in a laboratory setting."
